Phase 1 Completed N=66 Supportive Care

Marijuana in Combination With Opioids in Palliative and Hospice Patients

Postoperative Pain

Source: ClinicalTrials.gov NCT03233633 ↗

Enrolled (actual)

Serious AEs

1.5%

Results posted

Nov 2024

Primary outcomePrimary: Primary Reduction of Pain — 2.55; 1.40 units on a scale from 0 to 10

Summary

Study Objectives: Primary reduction of pain and reduction in overall opioid utilization. Secondary improvement in overall patient well being, weight stabilization with increased appetite, improved oxygen saturation, improvement or prevention of nausea and vomiting. Study Rationale: To determine optimum use and dosing of medical marijuana (CBD:THC) for pain and symptom management. Study Population: This study specifically will enroll cancer and non-cancer patients as a primary diagnosis suffering from pain and having a terminal illness (defined as having less than 6 months to live) requiring end of life care.

Outcome Measures

Outcome	Result	p-value
PRIMARY Primary Reduction of Pain	2.55; 1.40	—
PRIMARY Reduction in Overall Opioid Utilization	309.84; 285.54	—
SECONDARY Improvement in Overall Patient Well Being	3.31; 2.42	—
SECONDARY Weight Stabilization With Increased Appetite	1.93; 1.70	—
SECONDARY Improved Oxygen Saturation	94.86; 94.10	—
SECONDARY Reduction or Prevention of Nausea and Vomiting	0.46; 0.17	—

Eligibility Criteria

Inclusion Criteria

Age > 18
Alert adults
requiring opioids for pain management (routine)
cancer diagnosis or non-cancer diagnosis as their terminal illness

Exclusion Criteria

pregnant women
Age < 18
minimally or unresponsive patients unable to take oral medications
agitated combative patients

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03233633). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.